Special Edition SGLT-2 Inhibitors, March 2014

Typically when we have discussions about new drugs or drug classes they are not really discussions but presentations by someone on behalf of the manufacturer, and most of the questions are geared to promote the positive aspects of the new medication. In this month’s special edition covering SGLT-2 inhibitors, we have two independent perspectives from noted practitioners in the field: Dr. Stanley Schwartz discusses this new drug class in a Homerun Slides presentation, while Dr. John Anderson talks about future prospects for SGLT-2 inhibitors with our publisher, Steve Freed, in a Mastery In Minutes video interview.